Abcam, ab316307, Anti-CBLL1 antibody [EPR25389-121] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal HAKAI antibody. Carrier free. Suitable for WB, IP, IHC-P, ICC/IF, Flow Cyt (Intra) and reacts with Human, Mouse, Rat samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR25389-121,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human, Mouse, Rat,
Applications:IP, WB, Flow Cyt (Intra), ICC/IF, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab316307 is the carrirer-free version of
ab316306
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CBLL1 also known as Hakai is an E3 ubiquitin ligase. Its molecular weight is approximately 65 kDa and it functions by mediating ubiquitination which leads to the controlled degradation of target proteins. CBLL1 is expressed in several tissues including heart liver and kidney. The protein predominantly functions within the cytoplasm but can also translocate to the nucleus to exert its enzymatic activities.
Biological function summary
CBLL1 plays a significant role in cellular processes such as endocytosis cell adhesion and regulation of epithelial-mesenchymal transition (EMT). CBLL1 functions as part of a complex that helps target proteins for degradation through the ubiquitin-proteasome system. This activity is especially relevant in the regulation of cell signaling pathways where it targets various substrates such as E-cadherin for ubiquitination.
Pathways
CBLL1 is important in modulating signaling cascades like the Wnt and TGF-beta pathways. By influencing these pathways CBLL1 interacts with proteins like beta-catenin and SMADs. The degradation of E-cadherin by CBLL1 facilitates cellular detachment and migration a critical step in cellular processes regulated by these pathways.
CBLL1's involvement in the ubiquitin-proteasome system links it to cancer development and progression. The protein's regulation of EMT and cell adhesion implicates it in cancers such as gastric and colon cancers. Additionally CBLL1 interacts with proteins like beta-catenin in Wnt signaling which is often dysregulated in these cancers. Understanding the function of CBLL1 may offer potential therapeutic targets for combating these malignancies.